Progyny Participates in JP Morgan Healthcare Conference, Updates 2025 Performance Expectations
Progyny announced that the Company is participating in the 44th Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2025. "As the fourth quarter progressed, we were pleased to see that member engagement has paced favorably as compared to the guidance we issued in November," said Pete Anevski, Progyny's Chief Executive Officer. "Accordingly, we now expect our fourth quarter results for revenue, net income and Adjusted EBITDA to be slightly above the ranges that we provided in November, excluding any non-cash impacts to net income associated with the previously announced departure of Michael Sturmer as Progyny's president."
Trade with 70% Backtested Accuracy
Analyst Views on PGNY
About PGNY
About the author
Goldman Sachs Upgrades Enphase Energy to Buy, Raises Target to $45
- Analyst Rating Upgrade: Goldman Sachs analyst Brian Lee upgraded Enphase Energy (NASDAQ:ENPH) from Neutral to Buy and raised the price target from $29 to $45, reflecting confidence in its future growth potential.
- Intel Rating Adjustment: HSBC analyst Frank Lee upgraded Intel (NASDAQ:INTC) from Reduce to Hold and increased the price target from $26 to $50, indicating expectations for improved market performance.
- Progyny Market Performance Improvement: Citizens analyst Constantine Davides upgraded Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and set a price target of $30, suggesting optimism about its business growth.
- Brinker International Rating Upgrade: Morgan Stanley analyst John Glass upgraded Brinker International (NYSE:EAT) from Equal-Weight to Overweight and raised the price target from $160 to $200, reflecting a positive outlook on its future profitability.
Is Progyny's 85.7% Increase in 2025 Already Reflected in Its Growth Narrative?
Progyny's Stock Performance: Progyny's share price has increased significantly, up 50.2% year-to-date and 85.7% over the past year, driven by a growing focus on fertility benefits and a favorable market for scalable healthcare platforms.
Valuation Insights: Despite the stock's strong performance, Progyny scores only 2 out of 6 on valuation checks, indicating that the market may have already priced in much of the positive news.
Discounted Cash Flow Analysis: A Discounted Cash Flow model suggests that Progyny is undervalued by approximately 62.5%, with an intrinsic value of about $71.04 per share compared to its current trading price.
Price to Earnings Ratio: Progyny's current PE ratio of 40.6x is significantly higher than industry averages, indicating that the stock may be overvalued relative to its fundamentals, as the fair PE ratio is estimated at 26.3x.
